Taylor S H
Department of Medical Cardiology, General Infirmary, Leeds, England.
Am J Cardiol. 1988 Feb 10;61(5):34C-40C. doi: 10.1016/0002-9149(88)90482-1.
The introduction of beta-adrenoceptor antagonists was a major advance in the treatment of hypertension and coronary artery disease. However, nonselective beta blockade carries distinct circulatory disadvantages, which accounts for the search for an "ideal" beta-blocking drug for use in this extensive therapeutic field. It is possible to define the desirable cardiodynamic profile of a beta-blocking drug. How far does celiprolol meet this function? What questions should we address in attempting to evaluate the effects of celiprolol on the heart? In contrast to propranolol, in the normal heart, celiprolol does not depress left ventricular pumping function. There is little information on the effects of celiprolol on left ventricular function in the hypertensive patient. However, we now know that most patients with hypertension already have advancing coronary artery disease. It is reasonable, therefore, to examine the effects of celiprolol on left ventricular function in patients with coronary disease because these can not only be used to evaluate the possible efficacy of the drug in patients with angina pectoris, but also to extrapolate to their clinical effectiveness in most patients with hypertension. Celiprolol does not depress left ventricular pumping function at rest or during exercise, in contrast to other beta-adrenoceptor antagonists that reduce both heart rate and left ventricular activity. Moreover, celiprolol possesses anti-ischemic properties equivalent to those of atenolol. It does not appear to aggravate the atherogenic profile of the lipids as much as some other cardioselective beta-blocking drugs.(ABSTRACT TRUNCATED AT 250 WORDS)
β-肾上腺素能受体拮抗剂的引入是高血压和冠状动脉疾病治疗的一项重大进展。然而，非选择性β受体阻滞剂存在明显的循环系统缺陷，这促使人们在这一广泛的治疗领域寻找一种“理想”的β受体阻滞剂。可以定义一种β受体阻滞剂理想的心脏动力学特征。塞利洛尔在多大程度上符合这一功能？在评估塞利洛尔对心脏的影响时，我们应该解决哪些问题？与普萘洛尔不同，在正常心脏中，塞利洛尔不会降低左心室泵血功能。关于塞利洛尔对高血压患者左心室功能影响的信息很少。然而，我们现在知道大多数高血压患者已经患有进展性冠状动脉疾病。因此，研究塞利洛尔对冠心病患者左心室功能的影响是合理的，因为这不仅可以用于评估该药物对心绞痛患者的可能疗效，还可以推断其对大多数高血压患者的临床有效性。与其他降低心率和左心室活动的β-肾上腺素能受体拮抗剂不同，塞利洛尔在静息或运动时不会降低左心室泵血功能。此外，塞利洛尔具有与阿替洛尔相当的抗缺血特性。它似乎不像其他一些心脏选择性β受体阻滞剂那样会加剧脂质的动脉粥样硬化倾向。（摘要截短于250字）
